
ARVEE Latest Share Price (ARVEE)
TODAY IN ONE LINE
With a market cap of ₹244.64 Cr., it trades at a P/E of 69.87. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ARVEE flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 684.4% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 44.7% and Profit up 50.9%
- ●High Promoter HoldingPromoters hold 73.5% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.03x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 7.5%
- ●Rising Receivables vs SalesReceivables grew 37.5% outpacing sales growth of 26.8%
Latest ARVEE News
What changed recently?
Recent events, corporate actions, and announcements.
ARVEE valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ARVEE, framed against the sector median so the premium or discount is obvious at a glance.
ARVEE trades at a P/E of 69.87× and P/B of 5.22×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ARVEE technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ARVEE — derived from the latest tape, not yesterday's close.
ARVEE last traded at ₹228.06 with an intraday range of ₹218.05–₹238 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹228.06| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 277.92 | +49.86 | +21.86% |
| R3 | 257.97 | +29.91 | +13.12% |
| R2 | 247.99 | +19.93 | +8.74% |
| R1 | 238.02 | +9.96 | +4.37% |
| PIVOT | 228.04 | -0.02 | -0.01% |
| CURRENT | 228.06 | — | — |
| S1 | 218.07 | -9.99 | -4.38% |
| S2 | 208.09 | -19.97 | -8.76% |
| S3 | 198.12 | -29.94 | -13.13% |
| S4 | 178.17 | -49.89 | -21.87% |
ARVEE is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹–₹
Trading Inside opening range
ARVEE financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ARVEE — consolidated or standalone — with margins, YoY growth and key ratios inline.
ARVEE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹244.64 Cr. and reported EPS of ₹2.32.
ARVEE segment analysis : revenue and profit mix.
Disclosed business segments at ARVEE with their share of revenue and profit, switchable between consolidated and standalone reporting.
ARVEE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ARVEE.
Our AI distills the core fundamental drivers supporting ARVEE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ARVEE's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Minimal financial leverage with debt-to-equity ratio of 0.0003x indicates fortress-like balance sheet.
Net cash position of ₹38.81 Cr provides operational flexibility and financial cushion.
Current ratio of 3.35x signals strong liquidity to meet short-term obligations.
Diverse product portfolio spanning polymer modifiers, contrast media, and drug intermediates.
International export presence broadens revenue streams beyond domestic market concentration.
Key Risks.
Latest quarterly EPS grew 652.7% YoY but sales declined 29.4% YoY, signaling unsustainable volatility.
Operating margin of 6.41% TTM significantly lags peer averages of 10-15%, indicating weak pricing power.
P/E ratio of 90.92x TTM vastly exceeds peer median of ~30x, reflecting severe overvaluation.
Negative free cash flow per share of ₹0.1871 annually signals cash burn and liquidity deterioration.
ROE of 7.48% and ROCE of 4.71% substantially underperform sector averages of 15-20%.
Flip Conditions.
Valuation risk. a P/E above 91 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ARVEE peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ARVEE is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ARVEE chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ARVEE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ARVEE delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ARVEE over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ARVEE stood at 62.1% of traded volume, against a 20-day average of 59.9%.
ARVEE announcements: results, concalls, ratings, M&A.
Filings ARVEE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ARVEE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 31 documents below.
Appointment
Arvee Laboratories (India) Limited has informed the Exchange regarding Appointment of Mr Shalin Bharatbhai Chokshi as Executive Director of the…
Resignation
Arvee Laboratories (India) Limited has informed the Exchange regarding Resignation of Mr Saurin Ajitbhai Gandhi as Non- Executive Director of the…
Outcome of Board Meeting
Arvee Laboratories (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Delay/default in the payment of fines/penalties/dues etc. to authority
Arvee Laboratories (India) Limited has informed the Exchange about Delay/default in the payment of fines/penalties/dues etc. to authority
Shareholders meeting
Arvee Laboratories (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2025.…
ARVEE dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ARVEE has declared, sequenced by announce and record date.
ARVEE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ARVEE: business, sector, key facts.
What ARVEE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ARVEE operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: ARVEE.

Arvee Laboratories (India) Ltd. is a chemical manufacturing and distribution company based in Ahmedabad, India, established in 2012. Their primary business revolves around the production and sale of specialized chemicals both domestically within India and internationally through exports.
A significant portion of Arvee's product portfolio centers on polymer modifiers. These include a range of chemical compounds crucial in modifying the properties of polymers, enhancing their performance characteristics in various applications. Specific examples of these modifiers include dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate. The precise applications of these modifiers within the polymer industry are diverse and would require further technical detail to fully elaborate upon.
Another key area of Arvee's operations lies in the manufacturing of contrast media intermediates. These are chemical precursors used in the production of contrast agents, vital components in medical imaging techniques like X-rays and CT scans. The company produces a variety of these intermediates, including 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, dimethyl 5-aminoisophthalate, 3,5-dinitrobenzoic acid, and 3,5-diamino benzoic acid. This demonstrates a significant involvement in the pharmaceutical supply chain.
Furthermore, Arvee Laboratories also supplies drug intermediates. These are essential building blocks used in the synthesis of various pharmaceutical drugs. Their offerings in this category include 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4-aminopyridine, and 2-chloro-5-nitrobenzoic acid. This aspect of their business highlights their contribution to the broader pharmaceutical industry by providing crucial raw materials for drug manufacturing.
In summary, Arvee Laboratories is a key player in the specialty chemicals sector, serving both the polymer and pharmaceutical industries through the manufacturing and export of polymer modifiers, contrast media intermediates, and drug intermediates. Their diverse product portfolio and international reach solidify their position within the global chemical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- ADVANCE AGROLIFE (ADVANCE) Share PricePeer
- AGRO PHOS INDIA (AGROPHOS) Share PricePeer
- BAYER CROPSCIENCE (BAYERCROP) Share PricePeer
- BEST AGROLIFE (BESTAGRO) Share PricePeer
- BLACK ROSE INDS (BLACKROSE) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ARVEE (ARVEE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ARVEE (ARVEE)?
The current share price of ARVEE (ARVEE) is ₹228.06. Today, the stock has gained by ₹0.47 (0.21%), trading in a range of ₹218.05 to ₹238.00. The stock opened at ₹238.00 with a trading volume of 3,870 shares.
02Is ARVEE stock a good investment for long-term?
ARVEE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹244.64 Cr., P/E ratio of 69.87, ROE of 7.48%, and ROCE of 7.73%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ARVEE stock?
The 52-week high price of ARVEE (ARVEE) is ₹290.78, while the 52-week low is ₹129.11. Currently trading at ₹228.06, the stock is 76.64% above its 52-week low and 21.57% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ARVEE stock at the current price?
Whether to buy ARVEE stock at ₹228.06 depends on multiple factors. The stock is currently trading with a P/E ratio of 69.87 and P/B ratio of 5.22. Today's performance shows a gain of 0.21%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ARVEE and when is the next dividend?
ARVEE offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹228.06, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ARVEE?
ARVEE's key financial metrics include: P/E Ratio: 69.87, P/B Ratio: 5.22, ROE: 7.48%, ROCE: 7.73%, Dividend Yield: 0%, EPS: ₹2.32, Book Value: ₹30.66, and Debt-to-Equity: 0.03. The company's market cap stands at ₹244.64 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ARVEE stock performing today in the market?
ARVEE stock opened at ₹238.00 and is currently trading at ₹228.06, showing a gain of ₹0.47 (0.21%). The intraday high is ₹238.00 and low is ₹218.05. The trading volume stands at 3,870 shares, indicating moderate market participation today.
08What is the P/E ratio of ARVEE and what does it indicate?
ARVEE has a Price-to-Earnings (P/E) ratio of 69.87, which means investors are willing to pay 69.87 for every ₹1 of earnings. With an EPS of ₹2.32, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ARVEE (ARVEE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.